A flare of pre-existing erythema multiforme following BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine
- PMID: 33914926
- PMCID: PMC9213915
- DOI: 10.1111/ced.14714
A flare of pre-existing erythema multiforme following BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine
Figures
Comment in
-
Erythema multiforme-like reaction following COVID-19 vaccination.Indian J Dermatol Venereol Leprol. 2023 Jan-Frebuary;89(1):160. doi: 10.25259/IJDVL_791_2021. Indian J Dermatol Venereol Leprol. 2023. PMID: 35962494 No abstract available.
References
-
- Medicines and Healthcare products Regulatory Agency. Authorisation for temporary supply COVID‐19 mRNA vaccine BNT162b2. https://www.gov.uk/government/publications/regulatory‐approval‐of‐pfizer.... 2021. (accessed 30 March 2021).
-
- Trayes K, Love G, Studdiford J. Erythema multiforme: recognition and management. Am Fam Physician 2019; 100: 82–8. - PubMed
-
- Sokumbi OWD. Clinical features, diagnosis, and treatment of erythema multiforme: a review for the practicing dermatologist. Int J Dermatol 2012; 51: 889–902. - PubMed
-
- Chahal D, Aleshin M, Turegano M et al. Vaccine‐induced toxic epidermal necrolysis: a case and systematic review. Dermatol Online J 2018; 24: 13030/qt7qn5268s. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
